In addition, growth hormone (GH) and insulin growth factor-1 (IGF-1) may be decreased in NAFLD/NASH, which may contribute to the progression of sarcopenia, since IGF-1 produced in the liver has a muscle-retaining effect [55]. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.